Literature DB >> 28273452

Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer.

Koen M A Dreijerink1, Anna C Groner1, Erica S M Vos2, Alba Font-Tello1, Lei Gu3, David Chi1, Jaime Reyes4, Jennifer Cook1, Elgene Lim1, Charles Y Lin4, Wouter de Laat2, Prakash K Rao1, Henry W Long1, Myles Brown5.   

Abstract

While the multiple endocrine neoplasia type 1 (MEN1) gene functions as a tumor suppressor in a variety of cancer types, we explored its oncogenic role in breast tumorigenesis. The MEN1 gene product menin is involved in H3K4 trimethylation and co-activates transcription. We integrated ChIP-seq and RNA-seq data to identify menin target genes. Our analysis revealed that menin-dependent target gene promoters display looping to distal enhancers that are bound by menin, FOXA1 and GATA3. In this fashion, MEN1 co-regulates a proliferative breast cancer-specific gene expression program in ER+ cells. In primary mammary cells, MEN1 exerts an anti-proliferative function by regulating a distinct expression signature. Our findings clarify the cell-type-specific functions of MEN1 and inform the development of menin-directed treatments for breast cancer.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MEN1; breast cancer; enhancer; epigenetics; histone H3K4 trimethylation; menin; oncogene; transcription; tumor suppressor

Mesh:

Substances:

Year:  2017        PMID: 28273452      PMCID: PMC5609449          DOI: 10.1016/j.celrep.2017.02.025

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  66 in total

1.  c-Myb, Menin, GATA-3, and MLL form a dynamic transcription complex that plays a pivotal role in human T helper type 2 cell development.

Authors:  Yuji Nakata; Anne C Brignier; Shenghao Jin; Yuan Shen; Stephen I Rudnick; Mayumi Sugita; Alan M Gewirtz
Journal:  Blood       Date:  2010-05-18       Impact factor: 22.113

2.  Genome-wide analysis of estrogen receptor binding sites.

Authors:  Jason S Carroll; Clifford A Meyer; Jun Song; Wei Li; Timothy R Geistlinger; Jérôme Eeckhoute; Alexander S Brodsky; Erika Krasnickas Keeton; Kirsten C Fertuck; Giles F Hall; Qianben Wang; Stefan Bekiranov; Victor Sementchenko; Edward A Fox; Pamela A Silver; Thomas R Gingeras; X Shirley Liu; Myles Brown
Journal:  Nat Genet       Date:  2006-10-01       Impact factor: 38.330

Review 3.  Challenges and opportunities in targeting the menin-MLL interaction.

Authors:  Tomasz Cierpicki; Jolanta Grembecka
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

4.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

5.  Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.

Authors:  Ton van Agthoven; Anieta M Sieuwerts; Danielle Meijer; Marion E Meijer-van Gelder; Thecla L A van Agthoven; Roya Sarwari; Stefan Sleijfer; John A Foekens; Lambert C J Dorssers
Journal:  Endocr Relat Cancer       Date:  2010-02-18       Impact factor: 5.678

6.  Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription.

Authors:  Minna U Kaikkonen; Nathanael J Spann; Sven Heinz; Casey E Romanoski; Karmel A Allison; Joshua D Stender; Hyun B Chun; David F Tough; Rab K Prinjha; Christopher Benner; Christopher K Glass
Journal:  Mol Cell       Date:  2013-08-08       Impact factor: 17.970

7.  Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.

Authors:  Mathieu Lupien; Clifford A Meyer; Shannon T Bailey; Jérôme Eeckhoute; Jennifer Cook; Thomas Westerling; Xiaoyang Zhang; Jason S Carroll; Daniel R Rhodes; X Shirley Liu; Myles Brown
Journal:  Genes Dev       Date:  2010-10-01       Impact factor: 11.361

8.  Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.

Authors:  Say Li Kong; Guoliang Li; Siang Lin Loh; Wing-Kin Sung; Edison T Liu
Journal:  Mol Syst Biol       Date:  2011-08-30       Impact factor: 11.429

Review 9.  Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis.

Authors:  Valeria Busygina; Allen E Bale
Journal:  Yale J Biol Med       Date:  2006-12

10.  VAV3 mediates resistance to breast cancer endocrine therapy.

Authors:  Helena Aguilar; Ander Urruticoechea; Pasi Halonen; Kazuma Kiyotani; Taisei Mushiroda; Xavier Barril; Jordi Serra-Musach; Abul Islam; Livia Caizzi; Luciano Di Croce; Ekaterina Nevedomskaya; Wilbert Zwart; Josefine Bostner; Elin Karlsson; Gizeh Pérez Tenorio; Tommy Fornander; Dennis C Sgroi; Rafael Garcia-Mata; Maurice P H M Jansen; Nadia García; Núria Bonifaci; Fina Climent; María Teresa Soler; Alejo Rodríguez-Vida; Miguel Gil; Joan Brunet; Griselda Martrat; Laia Gómez-Baldó; Ana I Extremera; Agnes Figueras; Josep Balart; Robert Clarke; Kerry L Burnstein; Kathryn E Carlson; John A Katzenellenbogen; Miguel Vizoso; Manel Esteller; Alberto Villanueva; Ana B Rodríguez-Peña; Xosé R Bustelo; Yusuke Nakamura; Hitoshi Zembutsu; Olle Stål; Roderick L Beijersbergen; Miguel Angel Pujana
Journal:  Breast Cancer Res       Date:  2014-05-28       Impact factor: 6.466

View more
  26 in total

1.  Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma.

Authors:  Katarzyna Kempinska; Bhavna Malik; Dmitry Borkin; Szymon Klossowski; Shirish Shukla; Hongzhi Miao; Jingya Wang; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Mol Cancer Ther       Date:  2017-11-15       Impact factor: 6.261

2.  Long Noncoding RNA MEG3 Is an Epigenetic Determinant of Oncogenic Signaling in Functional Pancreatic Neuroendocrine Tumor Cells.

Authors:  Sucharitha Iyer; Sita D Modali; Sunita K Agarwal
Journal:  Mol Cell Biol       Date:  2017-10-27       Impact factor: 4.272

Review 3.  Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1.

Authors:  Koen M A Dreijerink; H T Marc Timmers; Myles Brown
Journal:  Endocr Relat Cancer       Date:  2017-08-15       Impact factor: 5.678

4.  RNA Binding Protein CUGBP1 Inhibits Liver Cancer in a Phosphorylation-Dependent Manner.

Authors:  Kyle Lewis; Leila Valanejad; Ashley Cast; Mary Wright; Christina Wei; Polina Iakova; Lauren Stock; Rebekah Karns; Lubov Timchenko; Nikolai Timchenko
Journal:  Mol Cell Biol       Date:  2017-07-28       Impact factor: 4.272

5.  Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.

Authors:  Annamaria Salvati; Viola Melone; Assunta Sellitto; Francesca Rizzo; Roberta Tarallo; Tuula A Nyman; Giorgio Giurato; Giovanni Nassa; Alessandro Weisz
Journal:  Breast Cancer Res       Date:  2022-07-18       Impact factor: 8.408

Review 6.  Recent Topics Around Multiple Endocrine Neoplasia Type 1.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

7.  Super-enhancer Acquisition Drives FOXC2 Expression in Middle Ear Cholesteatoma.

Authors:  Tomomi Yamamoto-Fukuda; Naotaro Akiyama; Hiromi Kojima
Journal:  J Assoc Res Otolaryngol       Date:  2021-04-16

8.  Nuclear Dishevelled targets gene regulatory regions and promotes tumor growth.

Authors:  Isabel Castro-Piedras; Monica Sharma; Jennifer Brelsfoard; David Vartak; Edgar G Martinez; Cristian Rivera; Deborah Molehin; Robert K Bright; Mohamed Fokar; Josee Guindon; Kevin Pruitt
Journal:  EMBO Rep       Date:  2021-04-16       Impact factor: 9.071

9.  The link between menin and pleiotrophin in the tumor biology of pancreatic neuroendocrine neoplasms.

Authors:  Liping He; Steeve Boulant; Megan Stanifer; Cuncai Guo; Anna Nießen; Mingyi Chen; Klaus Felix; Frank Bergmann; Oliver Strobel; Simon Schimmack
Journal:  Cancer Sci       Date:  2022-03-08       Impact factor: 6.518

10.  ADRENAL INCIDENTALOMA, BREAST CANCER AND UNRECOGNIZED MULTIPLE ENDOCRINE NEOPLASIA TYPE 1.

Authors:  S H Kim; J H Park
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.